Skip to main content
Premium Trial:

Request an Annual Quote

Planning, Precision, and Profit Margins

Holly at From Bench to Business highlights four questions any scientist-entrepreneur should ask themselves before beginning their own bio-business. First and foremost, she writes, those looking to make their science profitable should be prepared for the possibility of failure; sure, scientists are used to "little failures" on a day-to-day basis at the bench, but "I am asking how you would react to something you worked for a year on, for 14 hours a day, seven days a week?" Second, how would you handle a shift in focus away from science? "Many scientists I know are research purists," Holly writes, adding "if the project has to be changed in the name of profit, some would feel like they are 'selling out.'" Next, bio-business entrepreneurs must be willing to "create everything from scratch," including a flexible business plan covering all bases from human resources to sales to accounting, management, and customer service. Finally, scientists looking to break into business must be reasonable about their expectations: "The average business takes five years to become profitable," she notes.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.